Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Oct 26:2:131.
doi: 10.3389/fcimb.2012.00131. eCollection 2012.

Novel approaches to develop Rift Valley fever vaccines

Sabarish V Indran  1 , Tetsuro Ikegami
Affiliations
Review

Novel approaches to develop Rift Valley fever vaccines

Sabarish V Indran et al. Front Cell Infect Microbiol. .

Abstract

Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar, Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae, genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified as a Category A Priority pathogen and overlap select agent by CDC/USDA due to its potential impact on public health and agriculture. There is a gap in the safety and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this review, problems of traditional vaccines and the safety and efficacy of recently reported novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are discussed.

Keywords: Rift Valley fever virus; bunyavirus; phlebovirus; replicon; subunit vaccine; vaccine; vaccine vector.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ayari-Fakhfakh E., do Valle T. Z., Guillemot L., Panthier J. J., Bouloy M., Ghram A., et al. (2012). MBT/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines. J. Gen. Virol. 93, 1456–1464 10.1099/vir.0.042754-0 - DOI - PubMed
    1. Bhardwaj N., Heise M. T., Ross T. M. (2010). Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis. 4:e725 10.1371/journal.pntd.0000725 - DOI - PMC - PubMed
    1. Billecocq A., Gauliard N., Le May N., Elliott R. M., Flick R., Bouloy M. (2008). RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 378, 377–384 10.1016/j.virol.2008.05.033 - DOI - PMC - PubMed
    1. Bird B. H., Maartens L. H., Campbell S., Erasmus B. J., Erickson B. R., Dodd K. A., et al. (2011). Rift Valley fever virus vaccine lacking the NSs and NSm Genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J. Virol. 85, 12901–12909 10.1128/JVI.06046-11 - DOI - PMC - PubMed
    1. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., et al. (2001). Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J. Virol. 75, 1371–1377 10.1128/JVI.75.3.1371-1377.2001 - DOI - PMC - PubMed

Publication types

MeSH terms